

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

 In re E	Patent Δ	nnlicatio	n of							
In re Patent Application of:  Mary Ellen Rybak, et al.				al.	Examiner: Anne L. Holleran					
Serial	Serial No.: 09/904,263				Group Art Unit: 1642					
Filed:	July 1	2, 2001			Atty. Docket No.: OC01000KQ					
For:	For: MELANOMA THERAPY				: :					
			SUPPL	EMENTAL INFO	ORMATION DISCLOSURE STATEMENT					
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450										
Sir:										
(a) Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ⊠ are attached ☐ were filed in related application U.S. Serial No(s) filed, respectively.										
	(b)	$\boxtimes$	No fee	is believed due	e because:					
				This Information Disclosure Statement is being filed withree (3) months of the filing date of the application.						
				This Information	on Disclosure Statement is being concurrently bove-identified application.					
			$\boxtimes$	This Information	Disclosure Statement is being concurrently est for Continued Examination (RCE).					
				This Information	on Disclosure Statement is being filed prior to a first Office Action on the merits.					
	(c)		mailing	Information Dis g date of any fi vise closes pros	losure Statement is being filed before the al action, notice of allowance or an action that cution; and					
				Disclosure Sta a foreign pate	of information contained in this Information atement was first cited in a communication from nt office in a counterpart foreign application not ee months prior to the filing of this Information atement; or					
				Statement was office in a knowledge or inquiry, no ite Disclosure State in § 1.56(c) m	ormation contained in this Information Disclosure is cited in a communication from a foreign patent counterpart foreign application, and, to the find the undersigned after making reasonable and information contained in this Information attement was known to any individual designated hore than three months prior to the filing of this sclosure Statement; or					
				The Commis requisite fee li	sioner is hereby authorized to charge the sted on the attached Fee Transmittal Sheet.					
	(d)		This I payme	nformation Disc ent of the issue	closure Statement is being filed on or before the fee; and					

In re Application of: **Rybak,** et al. Serial No.: 09/904,263 Filed: July 12, 2001

2

	,,								
		Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or							
		No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and							
		The Commission requisite fee liste	oner is ed on the	hereby authorized to charge the attached Fee Transmittal Sheet.					
$\boxtimes$	required for this In Deposit Account I	nformation Disclosu	ıre Stat nt Case	narge any additional fees which may be stement, or credit any overpayment to se No. <u>OC01000KQ</u> . A DUPLICATE					
			•	Respectfully submitted,					
				SCHERING-PLOUGH CORPORATION					
Dated:	March 22, 2004		Ву:	Karen E. Brown					
SCHERING-PLOUGH CORPORATION Patent Department, K-6-1, 1990 2000 Galloping Hill Road Kenilworth, NJ 07033-0530 Facsimile No.: (908) 298-5388				Name: Karen E. Brown Reg. No.: 43,866 Attorney of Record Telephone No.: (908) 298-2902					

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: OC01000KQ APPLICANT:

APPLICATION NO.: 09/904,263

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Mary Ellen Rybak, et al.

D174112107411											
(Use several sheets if necessary)						FILING DATE:		GROUP: 1642			
						07/12/2001		11042			
	T			ATENT			- I - :	T - 2	I		
*EXAMINER		DOCUMENT	DATE		NAME		CLASS		FILING DATE IF APPROPRIATE		
INITIAL		NUMBER				<del></del> -		CLASS	APPRO	PRIATE	
	<u> </u>			<u> </u>	<u> </u>	<del></del>		<del> </del>	<del>                                     </del>		
<u> </u>			· ·		,			<del>                                     </del>	<del> </del>		
				<del> </del>			<del></del>	1			
		·	ODEIGN	IDATE	UT DOC	LIMENITS		. <del>1</del>		,	
	FOREIGN PATENT DOCUMENT DATE COUNTRY				OIVILIAIS	TCLASS	I SUR-	SUB- TRANSLATI			
		NUMBER		0001111	<b>\</b> 1		CLAGG	CLASS	YES	NO	
	<del> </del>	TTOMBET					<del></del>	102,00	1.20	1110	
							1			<u> </u>	
<del></del>										<u> </u>	
							j	İ		Ī	
	ОТІ	HER DOCUMENT	S (Includ	lina Aut	hor. Titl	e. Date. Pei	rtinent Pa	aaes. Et	c.)		
	AA	Bruno, René, et al.,								se II	
		Studies in Patients v	vith Cancer	," Journa	of Clinic	al Oncology 1	<b>6(1)</b> :187-96	5 (1998)			
	AB	AB Calvert, A.H., et al., "Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based Renal Function," <i>Journal of Clinical Oncology</i> <b>7(11)</b> :1748-56 (1989)							ed on		
	AC										
	<u> </u>	Therapeutic Potential," <i>Drugs</i> <b>55(1)</b> :5-30 (1998)  AD Eksborg, Steffan, <i>et al.</i> , "Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolit							40.0		
	AD										
comparison of bolus versus 2 h infusion during a 3 day course," <i>Anti-Cancer Drugs</i> 8:42  AE Forastiere, Arlene A., et al., "Pharmacokinetic and Toxicity Evaluation of Five-Day Conti							Continuo	1991)			
						mminedichloroplatinum(II) in Head and Neck Cancer					
		Patients," Cancer Re					.,				
	AF Gandhi, Varsha, et al., "Compound GW506U78 in Refractory Hematologic Malignancies:										
Relationship Between Cellular Pharmacokinetics and Clinical Response," <i>Journal of Clinical Oncology</i> <b>16(11)</b> :3607-15 (1998)								1			
AG Rodman, John H., et al., "Clinical Pharmacodynamics of Continuous Infusion Teniposide:  Systemic Exposure as a Determinant of Response in a Phase I Trial," Journal of Clinical											
	ŀ	Oncology <b>5(7)</b> :1007-			Respons	e in a Phase i	i riai," Jou	rnai of Cii	nicai		
	ΔН				icacy of	VC3340 accor	iated with	maintena	nce of		
	AH Shalinsky, David R., et al., "Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma								а		
concentrations," <i>Investigational New Drugs</i> <b>16</b> :303-13 (1999)								-			
	ΑI	Takitani, Kimitaka, e					ute Promy	elocytic L	eukemia	a in	
		Children with All-Tra	ns Retinoic	Acid The	erapy," J.	Nutr. Sci. Vita	minol. <b>41</b> :4	193-98 (19	995)		
EXAMINER	₹					ONSIDERED					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.